Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials

Journal:

The Lancet

Published:

2025-11-09

DOI:

10.1016/s0140-6736(25)02097-5

Affiliations:

6

Authors:

16

Go to article

Institutions	Authors	Share
Regeneron Pharmaceuticals, United States of America (USA)	11.000000 11.000000	0.69
OU Health Sciences Center (OUHSC), United States of America (USA)	1.000000	0.06
McMaster University, Canada	1.000000	0.06
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)	1.000000	0.06
The Thrombosis and Atherosclerosis Research Institute (TaARI), Canada	1.000000	0.06
ITREAS, Netherlands	1.000000	0.06

Interested in Oncology and Carcinogenesis?